Cambridge Investment Research Advisors
CRL icon

Cambridge Investment Research Advisors’s Charles River Laboratories CRL Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,162
Closed -$232K – 3959
2025
Q4 		$232K Sell
1,162
-167
-13% -$30.3K ﹤0.01% 3445
2025
Q3 		$208K Sell
1,329
-225
-14% -$35.7K ﹤0.01% 3454
2025
Q2 		$236K Sell
1,554
-372
-19% -$49.6K ﹤0.01% 3188
2025
Q1 		$290K Buy
1,926
+123
+7% +$20.6K ﹤0.01% 2892
2024
Q4 		$333K Sell
1,803
-175
-9% -$33.7K ﹤0.01% 2756
2024
Q3 		$390K Buy
1,978
+93
+5% +$19.3K ﹤0.01% 2615
2024
Q2 		$389K Buy
1,885
+158
+9% +$35.8K ﹤0.01% 2497
2024
Q1 		$468K Buy
1,727
+206
+14% +$49.2K ﹤0.01% 2330
2023
Q4 		$360K Sell
1,521
-197
-11% -$38.7K ﹤0.01% 2460
2023
Q3 		$337K Sell
1,718
-41
-2% -$8.42K ﹤0.01% 2415
2023
Q2 		$370K Buy
1,759
+414
+31% +$82.4K ﹤0.01% 2364
2023
Q1 		$271K Sell
1,345
-5,610
-81% -$1.27M ﹤0.01% 2574
2022
Q4 		$1.51M Buy
6,955
+215
+3% +$47K 0.01% 1252
2022
Q3 		$1.33M Buy
6,740
+5,181
+332% +$1.12M 0.01% 1288
2022
Q2 		$334K Sell
1,559
-35
-2% -$8.55K ﹤0.01% 2286
2022
Q1 		$453K Sell
1,594
-4,432
-74% -$1.37M ﹤0.01% 2189
2021
Q4 		$2.27M Sell
6,026
-238
-4% -$92.5K 0.01% 1069
2021
Q3 		$2.58M Buy
6,264
+2,718
+77% +$1.13M 0.01% 957
2021
Q2 		$1.31M Buy
3,546
+1,447
+69% +$483K 0.01% 1352
2021
Q1 		$608K Sell
2,099
-199
-9% -$55.3K ﹤0.01% 1758
2020
Q4 		$574K Buy
2,298
+691
+43% +$165K ﹤0.01% 1684
2020
Q3 		$364K Buy
+1,607
New +$334K ﹤0.01% 1803
2019
Q1 		– Sell
-9,422
Closed -$1.07M – 2293
2018
Q4 		$1.07M Sell
9,422
-100
-1% -$12.5K 0.01% 901
2018
Q3 		$1.28M Buy
+9,522
New +$1.18M 0.01% 893

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Cambridge Investment Research Advisors's CRL Position: Q1 2026 in Review

Cambridge Investment Research Advisors sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 1,162 shares — an estimated $232K sold.

Cambridge Investment Research Advisors first reported a position in CRL in Q3 2018 and held it in 24 quarters. The position peaked at $2.58M in Q3 2021. 559 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Cambridge Investment Research Advisors reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 1,162 Charles River Laboratories shares in Q1 2026, an estimated $232K.
  • Cambridge Investment Research Advisors first reported a position in Charles River Laboratories in Q3 2018 and held it in 24 quarters.
  • Cambridge Investment Research Advisors's Charles River Laboratories position peaked at $2.58M in Q3 2021.
  • 559 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.